Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Breast Neoplasms
  • Lymph Nodes
  • Neoplasms, Hormone-Dependent
  • Receptor, ErbB-2

abstract

  • Even among women with lower risk breast cancer, the relatively high locoregional failure rates associated with positive HER2 status could be reduced markedly with adjuvant trastuzumab chemotherapy. Within 3 years, a 10% LRR rate without trastuzumab and a 1% LRR rate with trastuzumab were observed in women with lymph node-negative disease who received BCT.

publication date

  • April 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.26484

PubMed ID

  • 21887681

Additional Document Info

start page

  • 1982

end page

  • 8

volume

  • 118

number

  • 8